Screener
Regeneron Pharmaceuticals REGN EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's EBITDA margin?
- Regeneron Pharmaceuticals (REGN) reported EBITDA margin of 28.1% in Q2 2026.
- How has Regeneron Pharmaceuticals's EBITDA margin changed year-over-year?
- Regeneron Pharmaceuticals's EBITDA margin decreased by 8.1% year-over-year, from 30.6% to 28.1%.
- What is the long-term trend for Regeneron Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's EBITDA margin has grown at a -8.5% compound annual growth rate (CAGR), from 44.9% to 28.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Regeneron Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude